MA50375A - Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 - Google Patents

Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2

Info

Publication number
MA50375A
MA50375A MA050375A MA50375A MA50375A MA 50375 A MA50375 A MA 50375A MA 050375 A MA050375 A MA 050375A MA 50375 A MA50375 A MA 50375A MA 50375 A MA50375 A MA 50375A
Authority
MA
Morocco
Prior art keywords
triazolo
pyrimidine
compositions containing
compounds used
pde2 inhibitors
Prior art date
Application number
MA050375A
Other languages
English (en)
Inventor
James Breitenbucher
Graeme Freestone
Laurent Gomez
Robert Lemus
Kiev Ly
Margaret Mccarrick
William Vernier
Troy Vickers
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of MA50375A publication Critical patent/MA50375A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA050375A 2014-04-23 2015-04-22 Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 MA50375A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983387P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
MA50375A true MA50375A (fr) 2021-05-26

Family

ID=53055118

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050375A MA50375A (fr) 2014-04-23 2015-04-22 Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2

Country Status (23)

Country Link
US (5) US9932345B2 (fr)
EP (2) EP3134413B1 (fr)
JP (1) JP6626449B2 (fr)
KR (1) KR102471058B1 (fr)
CN (2) CN110092788B (fr)
AU (2) AU2015249753B2 (fr)
BR (1) BR112016024713B1 (fr)
CA (1) CA2938294C (fr)
DK (2) DK3597649T3 (fr)
ES (2) ES2902806T3 (fr)
HR (1) HRP20212035T1 (fr)
HU (1) HUE057317T2 (fr)
IL (2) IL248292A (fr)
MA (1) MA50375A (fr)
MX (1) MX358004B (fr)
NZ (1) NZ725161A (fr)
PL (1) PL3597649T3 (fr)
PT (1) PT3597649T (fr)
RU (1) RU2659070C9 (fr)
SG (1) SG11201606216UA (fr)
SI (1) SI3597649T1 (fr)
TW (1) TWI664181B (fr)
WO (1) WO2015164508A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134413B1 (fr) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Composés de [1,2,4]triazolo[1,5-a]pyrimidin-7-yle substitués utilisables en tant qu'inhibiteurs de pde2
MX381417B (es) 2014-08-28 2025-03-12 Asceneuron Sa Inhibidores de glucosidasa.
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
CA3001768C (fr) * 2015-11-02 2022-12-13 Janssen Pharmaceutica Nv Compose [1,2,4]triazolo[1,5-a]pyridmidine-7-yl
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JP2019506430A (ja) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
WO2018083101A1 (fr) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv Composés de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2
KR20190070972A (ko) 2016-11-02 2019-06-21 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체
WO2018083103A1 (fr) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo[1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3555094A1 (fr) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Composés inhibiteurs d'oga bicyclique
AU2018223192A1 (en) * 2017-02-27 2019-06-20 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2020039029A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Composés spiro utilisés en tant qu'inhibiteurs de glycosidases
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
CA3110032A1 (fr) 2018-08-22 2020-02-27 Asceneuron S.A. Sels d'addition d'acide succinate et fumarate de derives de piperazine utiles en tant qu'inhibiteurs de glycosidase
US11814734B2 (en) 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
TWI907472B (zh) 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5478825A (en) 1991-02-22 1995-12-26 Egis Gyogyszergyar 5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives
HU208693B (en) 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
WO2002064211A1 (fr) 2001-02-09 2002-08-22 Merck & Co., Inc. Inhibiteurs de thrombine
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
WO2004044234A1 (fr) 2002-11-13 2004-05-27 Bayer Healthcare Ag Outils de diagnostics et therapeutique pour maladies associees a la phosphodiesterase 2a humaine (pde2a)
WO2004108136A1 (fr) 2003-06-04 2004-12-16 Vernalis (Cambridge) Limited Triazolo`1,5-a!pyrimidines et leur utilisation en medecine
WO2005041957A1 (fr) 2003-10-29 2005-05-12 Pfizer Products Inc. Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
EP1548011A1 (fr) 2003-12-23 2005-06-29 Neuro3D Dérivés de 1,4-benzodiazépine-2-one comme inhibiteurs de PDE2 phosphodiesterase, leurs préparation et utilisation thérapeutique
WO2006024640A2 (fr) 2004-09-02 2006-03-09 Altana Pharma Ag Triazolophtalazines
MX2007008137A (es) 2005-01-05 2007-07-19 Altana Pharma Ag Triazoloftalazinas como inhibidores de pde2.
JP5130053B2 (ja) 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
US7868016B2 (en) 2005-07-13 2011-01-11 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
CN101321758A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 用于治疗哮喘和慢性阻塞性肺病的新5,6－二氢吡唑并[3,4－e][1,4]二氮杂－4(1H)－酮衍生物
KR100844125B1 (ko) 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
AU2008254907A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US20100120763A1 (en) 2008-11-07 2010-05-13 Wyeth Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2010054253A1 (fr) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Dérivés de triazine en tant qu’inhibiteurs de phosphodiestérases
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
WO2011011312A1 (fr) 2009-07-22 2011-01-27 Merck Sharp & Dohme Corp. Inhibiteurs de quinoléinone pde2
EP2651405A2 (fr) 2010-12-14 2013-10-23 Electrophoretics Limited Inhibiteurs de caséine kinase 1 (ck1 )
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
JP5543039B2 (ja) * 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン
KR101626681B1 (ko) 2011-06-07 2016-06-01 화이자 인코포레이티드 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
WO2013034758A1 (fr) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazines substituées et leurs utilisations
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
WO2013034755A1 (fr) 2011-09-09 2013-03-14 H. Lundbeck A/S Dérivés de triazolopyrazine et leur utilisation pour le traitement de troubles neurologiques et psychiatriques
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CN103183675A (zh) * 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
EP3134413B1 (fr) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Composés de [1,2,4]triazolo[1,5-a]pyrimidin-7-yle substitués utilisables en tant qu'inhibiteurs de pde2
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物

Also Published As

Publication number Publication date
TW201625625A (zh) 2016-07-16
IL248292A (en) 2017-09-28
AU2015249753A1 (en) 2016-11-03
US12630556B2 (en) 2026-05-19
HUE057317T2 (hu) 2022-04-28
US20180179216A1 (en) 2018-06-28
US20230192698A1 (en) 2023-06-22
WO2015164508A4 (fr) 2015-12-23
JP6626449B2 (ja) 2019-12-25
IL254224B (en) 2019-01-31
JP2017513808A (ja) 2017-06-01
SG11201606216UA (en) 2016-09-29
IL254224A0 (en) 2017-10-31
CA2938294C (fr) 2023-02-21
ES2759246T3 (es) 2020-05-08
AU2019283994A1 (en) 2020-01-23
US11186582B2 (en) 2021-11-30
HRP20212035T1 (hr) 2022-04-01
CA2938294A1 (fr) 2015-10-29
WO2015164508A1 (fr) 2015-10-29
MX2016013860A (es) 2017-05-12
BR112016024713B1 (pt) 2023-05-02
CN106459062A (zh) 2017-02-22
KR20160145745A (ko) 2016-12-20
US20200095256A1 (en) 2020-03-26
AU2019283994C1 (en) 2021-12-09
NZ725161A (en) 2017-10-27
PL3597649T3 (pl) 2022-04-04
SI3597649T1 (sl) 2022-04-29
US9932345B2 (en) 2018-04-03
AU2019283994B2 (en) 2021-05-27
ES2902806T3 (es) 2022-03-29
EP3597649B8 (fr) 2022-02-16
RU2016143387A3 (fr) 2018-05-23
US20250092047A1 (en) 2025-03-20
EP3134413A1 (fr) 2017-03-01
AU2015249753B2 (en) 2019-10-10
RU2659070C2 (ru) 2018-06-28
BR112016024713A2 (pt) 2017-08-15
MX358004B (es) 2018-07-31
TWI664181B (zh) 2019-07-01
DK3597649T3 (da) 2022-01-10
EP3597649B1 (fr) 2021-10-13
EP3134413B1 (fr) 2019-09-11
CN110092788A (zh) 2019-08-06
US20170057967A1 (en) 2017-03-02
KR102471058B1 (ko) 2022-11-25
US10501465B2 (en) 2019-12-10
EP3597649A1 (fr) 2020-01-22
RU2016143387A (ru) 2018-05-23
PT3597649T (pt) 2022-01-21
CN110092788B (zh) 2022-02-25
DK3134413T3 (da) 2019-10-14
RU2659070C9 (ru) 2018-08-24

Similar Documents

Publication Publication Date Title
SI3597649T1 (sl) Sestavki, ki vsebujejo substituirane (1,2,4)triazolo(1,5-a)pirimidin-7-ilne spojine, kot zaviralci pde2
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
EP3328840A4 (fr) Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
DK3322706T3 (da) Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
ZA201607736B (en) Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
EA201891251A1 (ru) Бициклические ингибиторы pad4
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
ME03672B (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
EP3319966A4 (fr) Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ